JP2020503869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503869A5 JP2020503869A5 JP2019536508A JP2019536508A JP2020503869A5 JP 2020503869 A5 JP2020503869 A5 JP 2020503869A5 JP 2019536508 A JP2019536508 A JP 2019536508A JP 2019536508 A JP2019536508 A JP 2019536508A JP 2020503869 A5 JP2020503869 A5 JP 2020503869A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- sequence encoding
- nucleic acid
- guide rna
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 118
- 108020004707 nucleic acids Proteins 0.000 claims description 110
- 102000039446 nucleic acids Human genes 0.000 claims description 110
- 102100024108 Dystrophin Human genes 0.000 claims description 65
- 108020005004 Guide RNA Proteins 0.000 claims description 64
- 239000013598 vector Substances 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 44
- 108010069091 Dystrophin Proteins 0.000 claims description 27
- 108091033409 CRISPR Proteins 0.000 claims description 21
- 101710163270 Nuclease Proteins 0.000 claims description 21
- 201000006938 muscular dystrophy Diseases 0.000 claims description 15
- 210000003205 muscle Anatomy 0.000 claims description 14
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 241000702421 Dependoparvovirus Species 0.000 claims description 10
- 239000013603 viral vector Substances 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 1
- -1 DMD guide RNA (gRNA) Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 27
- 239000013607 AAV vector Substances 0.000 description 26
- 102000001039 Dystrophin Human genes 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 10
- 210000001087 myotubule Anatomy 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 5
- 230000002950 deficient Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 241000649045 Adeno-associated virus 10 Species 0.000 description 2
- 241000649046 Adeno-associated virus 11 Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 101150015424 dmd gene Proteins 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 101100443349 Homo sapiens DMD gene Proteins 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 208000000875 Spinal Curvatures Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762442606P | 2017-01-05 | 2017-01-05 | |
| US62/442,606 | 2017-01-05 | ||
| US201762544449P | 2017-08-11 | 2017-08-11 | |
| US62/544,449 | 2017-08-11 | ||
| US201762596298P | 2017-12-08 | 2017-12-08 | |
| US62/596,298 | 2017-12-08 | ||
| PCT/US2018/012558 WO2018129296A1 (en) | 2017-01-05 | 2018-01-05 | Optimized strategy for exon skipping modifications using crispr/cas9 with triple guide sequences |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020503869A JP2020503869A (ja) | 2020-02-06 |
| JP2020503869A5 true JP2020503869A5 (OSRAM) | 2021-02-12 |
Family
ID=61193018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536508A Pending JP2020503869A (ja) | 2017-01-05 | 2018-01-05 | トリプルガイド配列と共にｃｒｉｓｐｒ／ｃａｓ９を用いるエクソンスキッピング改変のための最適化戦略 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20190338311A1 (OSRAM) |
| EP (1) | EP3565897B1 (OSRAM) |
| JP (1) | JP2020503869A (OSRAM) |
| KR (1) | KR102606174B1 (OSRAM) |
| CN (1) | CN110506115A (OSRAM) |
| AU (1) | AU2018205521A1 (OSRAM) |
| BR (1) | BR112019013962A2 (OSRAM) |
| CA (1) | CA3048635A1 (OSRAM) |
| CL (1) | CL2019001882A1 (OSRAM) |
| CO (1) | CO2019008181A2 (OSRAM) |
| CR (1) | CR20190326A (OSRAM) |
| DK (1) | DK3565897T3 (OSRAM) |
| DO (1) | DOP2019000179A (OSRAM) |
| EC (1) | ECSP19056408A (OSRAM) |
| IL (1) | IL267786A (OSRAM) |
| JO (1) | JOP20190166A1 (OSRAM) |
| MA (1) | MA47239A (OSRAM) |
| MX (1) | MX2019008064A (OSRAM) |
| PE (1) | PE20191357A1 (OSRAM) |
| PH (1) | PH12019501561A1 (OSRAM) |
| SG (1) | SG11201906147VA (OSRAM) |
| WO (1) | WO2018129296A1 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| AU2016362282B2 (en) | 2015-11-30 | 2023-03-16 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| EP4275747A3 (en) | 2016-07-19 | 2024-01-24 | Duke University | Therapeutic applications of cpf1-based genome editing |
| KR102758434B1 (ko) * | 2017-03-30 | 2025-01-21 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 게놈 편집에 의한 엑손 스키핑 유도 방법 |
| EP3735462A1 (en) * | 2018-01-05 | 2020-11-11 | The Board of Regents of The University of Texas System | Therapeutic crispr/cas9 compositions and methods of use |
| US20210261962A1 (en) * | 2018-06-21 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2020122104A1 (ja) * | 2018-12-11 | 2020-06-18 | 国立大学法人京都大学 | ゲノムｄｎａに欠失を誘導する方法 |
| WO2020142714A1 (en) * | 2019-01-04 | 2020-07-09 | Exonics Therapeutics, Inc. | Aav expression cassette and aav vectors comprising the same |
| EP3935179A4 (en) * | 2019-03-07 | 2022-11-23 | The Trustees of Columbia University in the City of New York | Rna-guided dna integration using tn7-like transposons |
| EP3952884A4 (en) * | 2019-04-12 | 2023-03-22 | Duke University | Crispr/cas-based base editing composition for restoring dystrophin function |
| EP3952925A4 (en) * | 2019-04-12 | 2024-01-24 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR MODIFYING DYSTROPHIN GENES |
| EP3966327A1 (en) | 2019-05-08 | 2022-03-16 | Vertex Pharmaceuticals Incorporated | Crispr/cas all-in-two vector systems for treatment of dmd |
| KR102264115B1 (ko) * | 2019-05-10 | 2021-06-14 | 한국과학기술연구원 | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 |
| CN110499333A (zh) * | 2019-08-01 | 2019-11-26 | 广州德赫生物科技有限公司 | 用于修复dmd基因突变的核酸序列及系统 |
| WO2021072276A1 (en) * | 2019-10-11 | 2021-04-15 | Yale University | Compositions and methods for upregulating isoforms of dystrophin as therapy for duchenne muscular dystrophy (dmd) |
| KR102455623B1 (ko) * | 2019-10-29 | 2022-10-18 | 주식회사 진코어 | CRISPR/Cas12f1 시스템 효율화를 위한 엔지니어링 된 가이드 RNA 및 그 용도 |
| CN116096394A (zh) * | 2020-02-13 | 2023-05-09 | 特纳亚治疗股份有限公司 | 用于治疗心脏病的基因疗法载体 |
| CN111172191B (zh) * | 2020-02-21 | 2020-12-22 | 浙江大学 | 一种高效基因敲除载体及其应用 |
| JP2023515709A (ja) * | 2020-04-27 | 2023-04-13 | デューク ユニバーシティ | 筋肉特異的プロモーターをコードするａａｖベクターを使用するインビボでの衛星細胞の遺伝子編集 |
| CN112063621B (zh) * | 2020-09-02 | 2022-06-28 | 西湖大学 | 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用 |
| JP2023540783A (ja) * | 2020-09-09 | 2023-09-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | デュシェンヌ型筋ジストロフィーの治療のための組成物及び方法 |
| EP4366784A1 (en) | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| WO2023159103A1 (en) * | 2022-02-17 | 2023-08-24 | The Board Of Regents Of The University Of Texas System | CRISPR/SpCas9 VARIANT AND METHODS FOR ENHANCED CORRECTON OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS |
| KR20230134097A (ko) * | 2022-03-10 | 2023-09-20 | 주식회사 진코어 | Nhej 복구 경로 조절을 통해 핵산 세그먼트의 결실 효율을 증가시키기 위한 조성물 및 방법 |
| CN115820642B (zh) * | 2022-11-11 | 2023-10-10 | 昆明理工大学 | 一种用于治疗杜氏肌营养不良症的CRISPR-Cas9系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1997745A (zh) * | 2004-04-02 | 2007-07-11 | 得克萨斯州大学系统董事会 | 癌症特异性启动子 |
| SI3401400T1 (sl) | 2012-05-25 | 2019-10-30 | Univ California | Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja |
| KR20230136697A (ko) * | 2013-06-05 | 2023-09-26 | 듀크 유니버시티 | Rna-가이드 유전자 편집 및 유전자 조절 |
| DK3116533T3 (da) * | 2014-03-12 | 2020-08-24 | Prec Biosciences Inc | Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser |
| CA2959130A1 (en) * | 2014-08-11 | 2016-02-18 | The Board Of Regents Of The University Of Texas System | Prevention of muscular dystrophy by crispr/cas9-mediated gene editing |
| US20170266320A1 (en) * | 2014-12-01 | 2017-09-21 | President And Fellows Of Harvard College | RNA-Guided Systems for In Vivo Gene Editing |
| CA2972811A1 (en) * | 2015-01-16 | 2016-07-21 | University Of Washington | Novel micro-dystrophins and related methods of use |
| WO2016164356A1 (en) * | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| WO2016174056A1 (en) * | 2015-04-27 | 2016-11-03 | Genethon | Compositions and methods for the treatment of nucleotide repeat expansion disorders |
| CN108513546A (zh) * | 2015-10-28 | 2018-09-07 | 克里斯珀医疗股份公司 | 用于治疗杜氏肌营养不良症的材料和方法 |
| AU2016362282B2 (en) * | 2015-11-30 | 2023-03-16 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| US20170362635A1 (en) * | 2016-06-20 | 2017-12-21 | University Of Washington | Muscle-specific crispr/cas9 editing of genes |
-
2017
- 2017-06-16 JO JOP/2019/0166A patent/JOP20190166A1/ar unknown
-
2018
- 2018-01-05 WO PCT/US2018/012558 patent/WO2018129296A1/en not_active Ceased
- 2018-01-05 CA CA3048635A patent/CA3048635A1/en active Pending
- 2018-01-05 JP JP2019536508A patent/JP2020503869A/ja active Pending
- 2018-01-05 CN CN201880010288.7A patent/CN110506115A/zh active Pending
- 2018-01-05 KR KR1020197022753A patent/KR102606174B1/ko active Active
- 2018-01-05 AU AU2018205521A patent/AU2018205521A1/en not_active Abandoned
- 2018-01-05 DK DK18704637.0T patent/DK3565897T3/da active
- 2018-01-05 PE PE2019001384A patent/PE20191357A1/es unknown
- 2018-01-05 CR CR20190326A patent/CR20190326A/es unknown
- 2018-01-05 MA MA047239A patent/MA47239A/fr unknown
- 2018-01-05 MX MX2019008064A patent/MX2019008064A/es unknown
- 2018-01-05 EP EP18704637.0A patent/EP3565897B1/en active Active
- 2018-01-05 US US16/476,137 patent/US20190338311A1/en not_active Abandoned
- 2018-01-05 BR BR112019013962-1A patent/BR112019013962A2/pt unknown
- 2018-01-05 SG SG11201906147VA patent/SG11201906147VA/en unknown
-
2019
- 2019-07-02 PH PH12019501561A patent/PH12019501561A1/en unknown
- 2019-07-02 IL IL267786A patent/IL267786A/en unknown
- 2019-07-05 CL CL2019001882A patent/CL2019001882A1/es unknown
- 2019-07-05 DO DO2019000179A patent/DOP2019000179A/es unknown
- 2019-07-29 CO CO2019008181A patent/CO2019008181A2/es unknown
- 2019-08-06 EC ECSENADI201956408A patent/ECSP19056408A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503869A5 (OSRAM) | ||
| AU2023200175B2 (en) | Recombinant Adeno-Associated Virus Delivery Of Exon 2-Targeted U7snRNA Polynucleotide Constructs | |
| JP7069088B2 (ja) | アデノ随伴ウイルス変異体及びその使用方法 | |
| JP2019536782A5 (OSRAM) | ||
| US7943374B2 (en) | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb | |
| CN119613504A (zh) | 腺相关病毒变异衣壳和其使用方法 | |
| JP7541027B2 (ja) | 筋肉発現のためのハイブリッドプロモーター | |
| US20020076754A1 (en) | Overcoming AAV vector size limitation through viral DNA hetero-dimerization | |
| Cotmore et al. | Parvovirus DNA replication | |
| US20210308281A1 (en) | Combination therapy for spinal muscular atrophy | |
| WO2020142714A1 (en) | Aav expression cassette and aav vectors comprising the same | |
| JP2025540074A (ja) | 繰り返しエレメントの適切なパッケージングのためのアデノ随伴ウイルスベクター | |
| US20230357795A1 (en) | Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy | |
| CN115605266A (zh) | Dysferlin双载体的基因疗法 | |
| CN119403823A (zh) | 具有增强的肌肉转导效率的肽修饰的aav衣壳 | |
| WO2025023319A1 (ja) | 脳指向性ａａｖ変異体 | |
| JP2025534666A (ja) | 操作された核酸調節エレメントならびにその使用方法 | |
| WO2025019358A2 (en) | Mini-promoter compositions | |
| Rosas Rodríguez | Possible role of adenine and thymine rich sequence in the encapsidation pattern of Parvovirus LuIII | |
| HK1221962B (en) | Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs | |
| BR112015026579B1 (pt) | Vírus adeno associado recombinante e uso do mesmo |